Statins have been a very effective treatment to reduce adverse cardiovascular events in patients with or at high risk for ASCVD. Though RCTs do not support the much-increased risk of myopathy with Statin; in real world, we do see many patients who develop various muscle-related symptoms with or without CPK elevation. In many cases correcting coexisting issues like drug-interactions, hypothyroidism, Vitamin D3 deficiency do help the patient to tolerate at least some dose of one of the statins. What are the options for “really intolerant” patients?
Dr Anish Chandarana will highlight the issue with the most recent information. More discussion on this topic will happen during Joint International Conference, India (JIC). It is a great news for physicians that JIC 2018 is going to be held on Jan 5-7, 2018 at Ahmedabad, India . This year, JIC promises to be a truly enriching experience…
